Amivantamab-vmjw was approved with carboplatin and pemetrexed for locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, according to a March 1 news release from the agency.
It is the only drug approved for these mutations, MedPage reported March 4.
Leave a Reply